Therapy for headache in IIH is an urgent unmet need. This prospective, open-label, cohort study was carried to explore the efficacy of erenumab in managing chronic headaches in adult patients with IIH in clinical remission (resolved papilledema).
Erenumab proven effective to manage headache in
idiopathic intracranial hypertension (IIH) subjects with resolved papilledema.
Therapy for headache in IIH is an
urgent unmet need. This prospective,
open-label, cohort study was carried to explore the efficacy of erenumab in
managing chronic headaches in adult patients with IIH in clinical remission
(resolved papilledema).
The study cohort included 55 women having a confirmed diagnosis of chronic headaches, idiopathic intracranial hypertension in ocular remission and failure of more than three preventative therapeutics. These participants were administered with erenumab (70 mg) four-weekly injections.
The response was evaluated at
3-monthly follow-up consultations over twelve months. Alterations in monthly
moderate/severe headache days (MmsHD) from baseline (30-day pretreatment
period) to twelve months is the primary endpoint.
At twelve months, both MmsHD and monthly total headache days (MHD) considerably lowered, crystal clear days (days without any head pain) elevated, headache severity (Numeric rating scale [NRS] 0–10) and monthly analgesic days declined. All these measures had improved remarkably by three months, with a consistent vital response to 12 months, as shown in the following table:
A vital improvement was also
noted in both quality of life Short Form-36 Health Survey and the Headache
impact test-6 score, at 12 months. The sensitivity analysis illustrated
comparable outcomes for individuals with or without medication overuse (48%
[27/55] subjects) and those with and without a prior migraine diagnosis (52%
[28/55] subjects). In 38% (21/55) patients, side effects were witnessed.
The findings favored the use of erenumab for debilitating
headaches in idiopathic intracranial hypertension patients. Calcitonin
gene-related peptide appears to be a pivotal modulator driving headache and
therefore, a vital therapy target.
Headache: The Journal of Head and Face Pain
Erenumab for headaches in idiopathic intracranial hypertension: A prospective open‐label evaluation
Andreas Yiangou et al.
Comments (0)